Kenvue Inc. (NYSE:KVUE) Shares Sold by Retirement Systems of Alabama

Retirement Systems of Alabama decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 379,841 shares of the company’s stock after selling 9,837 shares during the period. Retirement Systems of Alabama’s holdings in Kenvue were worth $8,178,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Clearstead Advisors LLC purchased a new stake in shares of Kenvue in the third quarter valued at about $25,000. Planned Solutions Inc. acquired a new position in Kenvue during the 4th quarter worth approximately $27,000. Venturi Wealth Management LLC acquired a new position in Kenvue during the 3rd quarter worth approximately $28,000. EverSource Wealth Advisors LLC purchased a new position in shares of Kenvue during the 3rd quarter worth approximately $28,000. Finally, Cullen Frost Bankers Inc. acquired a new stake in shares of Kenvue in the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Up 0.4 %

Shares of KVUE stock opened at $19.20 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The firm has a 50-day moving average price of $19.82 and a 200 day moving average price of $20.11. Kenvue Inc. has a twelve month low of $17.82 and a twelve month high of $27.80.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. The business’s quarterly revenue was down 2.7% on a year-over-year basis. As a group, equities research analysts expect that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.17%. The ex-dividend date is Tuesday, May 7th.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several research analyst reports. Royal Bank of Canada decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. The Goldman Sachs Group began coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Sanford C. Bernstein assumed coverage on Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 price target on the stock. Finally, JPMorgan Chase & Co. dropped their price objective on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.